SUMMARY
Anticholinesterase (anti-ChE) pesticides are used to varying degrees in both developed and developing countries to improve crop yield, for vector control (e.g. mosquitoes), and in general household use. Anti-ChE exposures are an important cause of poisoning around the world, and organophosphorus pesticides are among the most toxic and common groups of pesticides associated with poisoning [1] [2] [3] [4] . Hundreds of thousands of people around the world die each year from organophosphorus pesticide poisoning, the majority in developing countries from intentional or occupational exposures 4 . In contrast, serious poisonings from organophosphorus pesticides are uncommon in developed countries, where most exposures are accidental.
Anti-ChE pesticides induce multi-system toxicity through inhibition of multiple esterases, but particularly acetylcholinesterase, causing accumulation of synaptic acetylcholine 5 . These toxic effects are well described, and are summarized in Table 1 . Carbamates are a less common cause of anti-ChE pesticide poisoning and rarely cause intermediate syndrome or organophosphus-induced delayed polyneuropathy. Most clinical effects result from acetylcholinesterase inhibition, but plasma cholinesterase (pseudocholinesterase) activity is also measured, being a sensitive marker of organophosphus exposure 5 . There is little published data on admissions to Australian hospitals with organophosphate poisoning because these exposures are infrequent. A survey of the literature revealed only one retrospective study from Australia (Perth) 6 . It is possible that presentations with organophosphate poisoning to Australian hospitals may increase in the future because of occupational, social and military factors. Users of organophosphate pesticides may be predisposed to toxicity because of background pseudocholinesterase inhibition 7 , which is a particular problem given the increased use of organophosphates by some industries 8 . Increasing rates of suicide in Australia 9 , may also increase the incidence of organophosphate poisonings. Finally, the ready access by terrorist groups to organophosphate compounds (such as sarin in the Tokyo Subway attack) has the potential to lead to mass exposures and severe toxicity [10] [11] [12] . Therefore, a level of awareness of clinical features of organophosphate poisoning and appropriate management is essential 11, 12 . Consequently, we felt that this area was worthy of review.
We conducted a retrospective study of all anticholinesterase pesticide exposures presenting to the Royal Brisbane and Women's Hospital, an Australian tertiary referral hospital. The purpose of this paper is to describe experiences with organophosphate pesticide poisoning at this hospital, and to highlight important considerations in the treatment of patients exposed to these pesticides.
MATERIALS AND METHODS
All patients admitted to the Royal Brisbane and Women's Hospital with an exposure to an anticholinesterase pesticide between January 1990 and June 2003 were included. Patients were identified by discharge diagnosis coding using the International Classification of Diseases criteria.
Information was retrospectively obtained by manual review of patient medical charts. A predesigned case record form identified relevant clinical details. The results of laboratory investigations were obtained through computer records, including anticholinesterase and pseudocholinesterase activity, blood gas analysis and biochemistry, where available. Exposure was confirmed by the history, clinical effects and the need for and response to antidotes.
A number of tools to classify the severity of acute toxicity from anticholinesterase agents have been suggested. For these tools to be properly applied, various pieces of clinical information or certain investigations (e.g. cholinesterase activities, chest X-ray or blood gases) are required. This data may not be readily available on retrospective chart review or performed 10-20% of the loading dose every hour, but regularly review the patient to ensure that atropinization is maintained and that atropine toxicity does not develop.
• Wash pesticide spills from the patient with soap and water.
• Gastric emptying may be considered for presentations within 1-2 hours.
• Activated charcoal (50 g po or ng) may be given if the patient is cooperative or intubated, generally for patients admitted within 1-2 hours or with severe toxicity.
• The WHO recommends a loading dose of 30 mg/kg pralidoxime chloride over 20 minutes, followed by an infusion of 8-10 mg/kg/hour until recovery (12 hours after the last dose of atropine), or for a total of seven days, which ever is less. (The use of pralidoxime is controversial (see text).) • Regular monitoring of the patient and adequacy of atropine dose is essential, particularly during the first six hours of admission.
Intermediate syndrome (IMS) 5, 35 Characterized by facial, proximal limb and respiratory muscle weakness, Commencing 1-4 days after exposure, and lasting between five and 18 days. It occurs in the interval between the acute cholinergic syndrome and the development of a delayed motor neuropathy. The pathogenesis of IMS is unclear. Early detection is vital, given that it is associated with respiratory failure and a requirement for ventilation. There is no specific treatment for this toxicity; management consists of supportive care. 5 Noted 1-3 weeks after an acute exposure, but after a more variable interval following chronic exposure. Cramping muscle pain in the legs is the usual initial complaint of OPIDP, sometimes followed by numbness and paraesthesiae in the distal parts of the limbs. Acute weakness of the feet and legs then occurs, followed by weakness of the hands and forearms. Sensory loss may develop in the extremities, but is usually mild. In some cases, this polyneuropathy may be chronic. There is no specific treatment for this toxicity; management consists of supportive care.
OP-induced delayed polyneuropathy (OPIDP)
in all patients as standard care, causing difficulty with use of the tool. Therefore, a simplified method to classify exposures was used. In terms of clinical outcomes and treatment, we divided cases into those with or without severe effects. Severe effects in the context of anticholinesterase poisoning were defined as any of the following: a) respiratory failure requiring ventilatory support, b) hypotension requiring inotropes, c) depressed level of consciousness (Glasgow Coma Score <12), d) seizures, e) death.
Data were grouped into severe and non-severe poisonings. Continuous variables in these groups were compared using the Mann-Whitney test. Categorical variables were compared by the Fisher's exact test for comparisons. A P<0.05 was taken as statistically significant.
RESULTS
Between January 1990 and June 2003 there were 47 presentations to the Royal Brisbane and Women's Hospital coded as anticholinesterase pesticide exposure. Six (13%) of these patients were exposed to other pesticides, including amitraz, glyphosate, endosulfan, dinitroaniline and MCPA (4-chloro-2-methylphenoxyacetic acid) with dicamba, but miscoded as anticholinesterase pesticides. The remaining 41 patients were considered to be anticholinesterase exposures.
Demographics, clinical details, investigations, outcomes and statistical significance are shown in Table  2 . Chronic exposure was noted in one patient with severe poisoning, while all other exposures were acute. One patient died in this series, corresponding to an overall mortality of 2.4%.
Gastrointestinal effects (mostly diarrhoea, but also nausea and vomiting) were the most common muscarinic symptoms in both groups. Two patients with severe poisoning demonstrated nicotinic toxicity without muscarinic features. The correlation between cholinesterase activity and poisoning severity was noted to be poor (Figures 1 and 2 * Median length of stay until cleared medically of significant anticholinesterase toxicity. The official length of stay was adjusted for two patients who were cleared of organophosphate toxicity early, but remained an inpatient for other issues. One patient required a seven day surgical admission, but was toxicologically cleared by 24 hours. Another patient's admission was reduced to 6 hours because this was the point where significant organophosphate toxicity was excluded. # 7 patients with severe poisonings and 13 patients with non-severe poisonings had cholinesterase activity measured . monitored by clinical examination, spirometry and/or biochemical investigations such as arterial blood gas, electrolytes and blood cholinesterase activity.
Severe poisonings
The culprit organophosphate was identified in six exposures: chlorpyrifos (3), diazinon (2), and fenthion (1). Oral exposure accounted for six cases, and dermal or inhalational exposure in the other two cases. One patient who had advanced dementia was not admitted to Intensive Care Unit (ICU), and died of respiratory failure despite non-invasive ventilation. Six of the patients admitted to ICU were transferred from a peripheral hospital. The diagnosis was delayed in four (50%) patients: three patients had a de- 
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background of increasing cholinergic toxicity until seizures, hypotension and severe diarrhoea prompted hospital admission. This was thought to result from chronic low-level trichlorfon exposure at home, although this could not be confirmed. There was no other cause for neurotoxicity, cholinesterase activity was low, and intentional organophosphate poisoning was unlikely.
Elevated lactate was presumed to be secondary to hypotension (three patients) and seizures (two patients). Two cases of aspiration pneumonia and one nosocomial pneumonia in the setting of a prolonged admission were recorded.
Non-severe poisonings
Two patients were referred by a general practitioner, one was transferred from a peripheral hospital, and the others self-presented. Twenty-nine patients were exposed to an organophosphate: chlorpyrifos (12), diazinon (8), malathion (3), methylparathion (2), coumaphos, methidathion, famphur, and dimethoate (one each). Two patients were exposed to a carbamate pesticide (propoxur and bendiocarb), and two patients were exposed to an unknown anticholinesterase.
Patients with non-severe poisoning exhibited only mild cholinergic toxicity on admission. Three patients were admitted to the ICU, one following elective intubation for gastric lavage and the other two as a precaution. With the exception of a few patients admitted to the ward, all others were managed in the Emergency Department. Few patients required specific antidote treatments for cholinergic toxicity. Close observation was the most important management for this group. Patients at risk of toxicity on the basis of history were monitored for 12 or more hours, and discharged home with a median length of stay of 24 hours.
Fourteen patients reported dermal exposures and symptoms developed in eight of these, generally within 60 to 180 minutes post-exposure in the absence of decontamination. One patient developed cholinergic toxicity 16 hours after dermal exposure to chlorpyrifos. Four patients reported an inhalational exposure, 13 had oral exposures, intravenous administration (with extensive extravasation) was attempted by one patient and in one case of suspected poisoning, the route of exposure was unknown.
Patients with normal cholinesterase activity were observed for a shorter time than those with depressed activity, corresponding to median admission times of 12 and 24 hours respectively. There were no other overall differences in outcome. While normal cholinesterase activity could also be consistent with early presentation, or early testing in exposure to a thion organophosphate (as in three patients), none of these patients returned to the Royal Brisbane and Women's Hospital with cholinergic toxicity. Blood tests were not obtained in 14 patients (34% of all admissions).
Fourteen patients (34% of admissions) presented to hospital with an exposure of very limited duration or volume, or an extended time after an exposure. These exposures, as reported in the medical chart, suggested a low likelihood of significant toxicity. Symptoms were reported by some, but these appeared consistent with either anxiety or a concomitant injury. None of these patients received specific antidotes, blood tests were rarely obtained, and symptoms generally appeared to resolve with reassurance. They were cleared of significant anticholinesterase poisoning within a median of seven hours, and those without other injuries were discharged home. None re-presented to the Royal Brisbane and Women's Hospital with cholinergic toxicity.
DISCUSSION
This paper reports 14 years' experience with anticholinesterase pesticide poisoning by the Royal Brisbane and Women's Hospital, an 942 bed tertiary referral teaching hospital in Queensland. This hospital provides general and specialist services to patients throughout the state and beyond. Critical care retrieval services and other emergency medical air transfers in south east Queensland were also coordinated by this hospital during the study period. In 2002, poisonings accounted for about 1.3% of all presentations to the Emergency Department and about 7.0% of all admissions to ICU.
The management of organophosphate poisoning consists of supportive care, atropinisation, and appropriate decontamination (Table 1) . In mild poisonings, prevention of further exposure (removal from source of exposure and adequate decontamination) and administration of low-dose atropine may be sufficient treatment. In severe poisonings, following appropriate resuscitation and decontamination, patients are best managed in an ICU for close observation (this is essential given that toxicity such as respiratory failure may have a delayed onset) 13 , advanced cardiorespiratory management, and careful titration of antidotes. The acute cholinergic syndrome is potentially reversible with adequate doses of anticholinergic drugs. Prompt administration of oximes such as pralidoxime may reverse muscle weakness or paralysis. Established intermediate syndrome and organophos-phate-induced delayed polyneuropathy do not respond to antidotes; instead supportive care is the priority.
Comparison with Other Published Data
Most anticholinesterase pesticide poisonings are reported from developing countries, reflecting the frequency and severity of such poisonings in these areas. In contrast, anticholinesterase poisonings are relatively infrequent in developed countries such as Australia 6 . For perspective, over 14 years the number of cases treated at RBWH was similar to those treated within 1-2 months by a single hospital in parts of Sri Lanka 3 , India 14 and China 15 . While this may suggest limited experience by Australian clinicians, outcomes in our patients were favourable where the overall mortality was 2.4%, similar to that noted in other Australian centres 6 . A concern is whether the low incidence of anticholinesterase poisonings in Australia may lead to a delay in diagnosis, as noted in 4/8 (50%) of patients with severe poisonings in our series, and by others previously 16, 17 . This delay did not appear to adversely affect patient outcomes or put hospital staff at risk of secondary (nosocomial) poisoning, but highlights the importance for clinicians to be familiar with features of organophosphate poisoning. The incidence of secondary poisoning to clinical staff managing organophosphate poisonings is rare and prevented through use of universal precautions 18, 19 . Staff in whom secondary contamination is suspected should be managed in the same manner as patients with an acute poisoning, including measuring cholinesterase activity to determine the significance of the exposure.
Intermediate syndrome was noted in 5% of all patients in our series, similar to that reported in China (7%) 15 and India (3%) 14 . The other Australian study reviewed 10 years experience with organophosphate poisonings at all Perth hospitals 6 . This included a large number of asymptomatic children which increased the baseline population used for calculation of proportions, while making comparison with our adult population data difficult. Further, exposures in this series were classified for comparative purposes on the reason for poisoning (suicide or accidental). This classification did not predict poisoning severity with sufficient accuracy, consistent with our findings, and made other comparisons difficult. There appears to be a higher proportion of patients with severe poisoning in the Perth series compared to our experiences. No reference was made to the incidence of intermediate syndrome or organophosphate-induced delayed polyneuropathy.
Clinical Features
The acute cholinergic syndrome is noted in all significant exposures. Most patients in this series were symptomatic within a few hours, except one patient whose symptoms were delayed 16 hours following dermal exposure to an organophosphate that required bioactivation. Gastrointestinal symptoms were most prevalent with oral exposures, probably an effect of high pesticide concentrations in the gut prior to absorption 5 , and the hydrocarbon solvent. Respiratory failure requiring ventilation, tachycardia, weakness and metabolic acidosis were common manifestations of severe poisoning in our series. Tachycardia did not appear to correlate with hypotension or pneumonia; instead it may be secondary to catecholamine release from the adrenal medulla under nicotinic stimulation 20 . Various tools have been proposed to classify organophosphate poisoning severity on clinical features 2, 5, 21, 22 , but they have not been widely adopted 5 . Most do not include acidosis, tachycardia or blood pressure changes to define severe poisoning, as noted in our study. Further development of these tools may allow their use to determine treatment and predict outcomes 2 .
Administration of Antidotes
Pralidoxime continues to be used widely in Australia and other parts of the world even though efficacy is unclear 6, 13, 14, 23, 24 . Some argue that oximes may actually potentiate organophosphate toxicity 25 . In our study pralidoxime was administered to most patients with neuromuscular effects, even in non-severe poisonings where atropine was not required. Variable dosing regimens were noted here, which has also been noted in other institutions across the world, probably due to confusion over the optimum dose 24 . Atropine was also administered in various regimens. Development and distribution of validated treatment protocols may guide treatment of infrequent poisonings such as anticholinesterase pesticides.
Pseudocholinesterase activity is a sensitive marker of anticholinesterase poisoning 5, 26 . It can confirm a significant exposure on presentation, which may assist management. Documentation of pseudocholinesterase activity may also have forensic implications if neuropathy or cognitive deficits develop later. For example, it is unlikely that exposure to an anticholinesterase pesticide would be the cause of chronic disability if pseudocholinesterase activity is documented to be normal.
The mortality observed in our series is consistent with data from other studies which report anywhere from 4% to 30% 5 . This wide variation may reflect differences in degree of exposure, rates of reporting, resources (including experienced clinicians, facilities and antidotes), genetics, or differences between individual anticholinesterase pesticides 5, 27, 28 . Finally, the mechanism of toxicity for organophosphate pesticides is identical to organophosphate chemical warfare nerve agents including VX, tabun and sarin. Experience from the Tokyo subway incident highlighted the role of the hospitals in the diagnosis, triage and primary management of the majority of people potentially exposed to the chemical agent. Preparation for mass exposures such as that seen in this incident requires measures that develop the skills and knowledge of medical staff, supplemented by validated treatment protocols 11, 12, 29, 30 . Many Australian hospitals may not be adequately prepared to respond to such a mass exposure 31 . Some guidelines and training are provided by Emergency Management Australia (EMA), but local plans are determined by individual hospitals and health services 12 .
CONCLUSION Anticholinesterase pesticide exposures are uncommon in Australia, particularly severe poisonings requiring ICU admission. Supportive care, appropriate decontamination and antidotes remain the treatment priority. Common manifestations of severe toxicity include requirement for ventilatory support, nicotinic toxicity (particularly tachycardia), and metabolic acidosis. Measurement of cholinesterase activity can identify significant exposures and assist with acute management, but may also have forensic implications if adverse effects are reported. Cholinesterase activity does not appear to be a useful predictor of poisoning severity. Despite the low incidence of anticholinesterase poisoning and delays in diagnosis noted in Australia, the outcomes for anticholinesterase poisoning are favourable in our institution.
The development of the skills and knowledge of medical staff, and validated treatment protocols, appears to be necessary. For example decontamination skills may be developed through application of established simulation techniques 32 . These are also useful when preparing for mass exposures to anticholinesterase pesticides or chemical warfare agents.
